Cellectar Biosciences
CLRB
23 hedge funds and large institutions have $3.85M invested in Cellectar Biosciences in 2020 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 4 closing their positions.
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
99% more capital invested
Capital invested by funds: $1.94M → $3.85M (+$1.91M)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
44% more funds holding
Funds holding: 16 → 23 (+7)
0.01% less ownership
Funds ownership: 0.05% → 0.04% (-0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$781K |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$558K |
| 3 |
SCM
Sio Capital Management
New York
|
+$265K |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$196K |
| 5 |
QP
Quilter Plc
London,
United Kingdom
|
+$192K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$71K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$15K |
| 3 |
Morgan Stanley
New York
|
-$14.3K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$4K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Bank of America
Charlotte,
North Carolina
| – | -$2K | -5 | Closed |
|
CLRB Hedge Fund Activity: Q2 2020 in Review
23 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q2 2020, worth a combined $3.85M — up 99% from $1.94M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CLRB positions and 4 closed out — a net gain of 7 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $781K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $71K sold.
- 23 institutional investors held Cellectar Biosciences (CLRB) as of Q2 2020, up from 16 in Q1 2020.
- Funds reported $3.85M of Cellectar Biosciences stock for Q2 2020, up 99% quarter-over-quarter.
- 11 funds opened new Cellectar Biosciences positions in Q2 2020 and 4 closed out, a net change of +7 holders.
- The largest Cellectar Biosciences buyer in Q2 2020 was Renaissance Technologies, an estimated $781K added.
- The largest Cellectar Biosciences seller in Q2 2020 was Susquehanna International Group, an estimated $71K sold.
Based on aggregated 13F filings for Q2 2020.